Phase 1 N=32 Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.
Effect of Atorvastatin on the Pharmacokinetics of Lomitapide
Primary: Cmax — 0.940; 2.00; 2.24; 2.11 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=15 A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc
HIV Infection · HIV-1 Infection · Mycobacterium Avium Complex (MAC)
Primary: Pharmacokinetics of Maraviroc and Rifabutin AUC 0-12/24 — 1026.2; 847.0; 4221.9; 331.9 h*μg/L
Phase 1 N=120 Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Endometrial Adenocarcinomas · Neuroendocrine Tumors · Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
Primary: Maximum Tolerated Dose (MTD) — 50; 50; 5.0; 5.0 DOX mg/m2 PM01183 mg FD
Phase 1 N=77 Relative Bioavailability Study of Emodepside IR-tablets and Solution
Filariasis
Primary: PK (AUC0-7d) of Two New Tablet Formulations of Emodepside in Comparison to the Liquid Formulation (LSF) Oral Solution. — 1215; 852; 931; 674 h.ng/ml
Phase 1 N=28 A Study to Investigate the Bioequivalence of Two Different Forms of Entrectinib (Forms A and C) Under Fasted Conditions in Healthy Subjects
Healthy Volunteers
Primary: Area Under the Concentration-Time Curve (AUC0-t) of Entrectinib and M5 Metabolite — 18500; 16600; 3610; 3070 nmol*h/L
Phase 1 N=21 Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Duct Cell Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage III Pancreatic Cancer
Primary: Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the…
Phase 1 N=17 BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
HER2-positive Breast Cancer · Recurrent Breast Cancer · Stage IIIA Breast Cancer
Primary: Dose Limiting Toxicity (DLT) of Dose-escalating BYL719 in Combination With T-DM1 — 0; 1; 0; 2 Participants
Phase 1 N=164 Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
Staphylococcal Infections · Yeast Infections · Candidiasis
Primary: Number of Participants With Treatment Emergent Adverse Events — 35; 33; 30; 36 participants
Phase 1 N=5 MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)
HIV-1 Infection
Primary: Number of Participants With at Least One Adverse Event (AE) — 4 Participants
Phase 1 N=64 Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
Acute Myelogenous Leukemia
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 32; 29; 3; 21 Participants
Phase 1 N=11 Doravirine, Rifapentine and Isoniazid Interaction
Latent Tuberculosis · Human Immunodeficiency Virus · Rifamycins Causing Adverse Effects in Therapeutic Use
Primary: Doravirine Maximum Concentration (Cmax) — 1.7; 1.3 ug/mL
Phase 1 N=18 A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
Healthy Volunteers · Chronic Kidney Disease
Primary: Effect of RBT-3 on Plasma Ferritin Levels — 2.49; 4.42; 4.90 Ratio (24 h post-infusion over baseline)
Phase 1 N=44 Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Mean Change From Time-Matched Baseline in QTcI, Individual Baseline Corrected Rate-Corrected QT Interval — -1.3; -7.7; -1.1; -2.0 msec
Phase 1 N=28 A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants
Hepatitis B Virus
Primary: Percentage of Participants With Adverse Events — 16.7; 0; 30.0; 10.0 Percentage of Participants
Phase 1 N=22 Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
Hepatic Impairment · Healthy
Primary: Cmax — 538.1; 533.4; 429 ng/mL